152 related articles for article (PubMed ID: 12505598)
1. Role of weekly paclitaxel in the treatment of advanced ovarian cancer.
Thomas H; Rosenberg P
Crit Rev Oncol Hematol; 2002 Dec; 44 Suppl():S43-51. PubMed ID: 12505598
[TBL] [Abstract][Full Text] [Related]
2. Weekly paclitaxel in the treatment of recurrent ovarian cancer.
Baird RD; Tan DS; Kaye SB
Nat Rev Clin Oncol; 2010 Oct; 7(10):575-82. PubMed ID: 20683437
[TBL] [Abstract][Full Text] [Related]
3. Dose-dense paclitaxel in advanced ovarian cancer.
Kumar A; Hoskins PJ; Tinker AV
Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):40-7. PubMed ID: 25455846
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel in the management of ovarian cancer.
Markman M
Semin Oncol; 2000 Jun; 27(3 Suppl 7):37-40. PubMed ID: 10952125
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
[TBL] [Abstract][Full Text] [Related]
6. Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer.
Alberola V; Cortesi E; Juan O
Crit Rev Oncol Hematol; 2002 Dec; 44 Suppl():S31-41. PubMed ID: 12505597
[TBL] [Abstract][Full Text] [Related]
7. Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer.
Lück HJ; Roché H
Crit Rev Oncol Hematol; 2002 Dec; 44 Suppl():S15-30. PubMed ID: 12505596
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
9. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
[TBL] [Abstract][Full Text] [Related]
11. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
12. Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis.
Marchetti C; De Felice F; Musella A; Palaia I; Monti M; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Oncotarget; 2016 Sep; 7(36):58709-58715. PubMed ID: 27509061
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
[TBL] [Abstract][Full Text] [Related]
14. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
Vermorken JB
Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
Wiseman LR; Spencer CM
Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
20. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
Dalton HJ; Yu X; Hu L; Kapp DS; Benjamin I; Monk BJ; Chan JK
Gynecol Oncol; 2012 Feb; 124(2):199-204. PubMed ID: 22055763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]